Clinical Trials Logo

Chronic Hepatitis C clinical trials

View clinical trials related to Chronic Hepatitis C.

Filter by:

NCT ID: NCT03941821 Not yet recruiting - Chronic Hepatitis c Clinical Trials

Glecaprevir/Pibrentasvir Real-world Study in China

Start date: June 30, 2019
Phase:
Study type: Observational

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

NCT ID: NCT03903081 Recruiting - Chronic Hepatitis C Clinical Trials

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects

HEC110114
Start date: March 6, 2019
Phase: Phase 1
Study type: Interventional

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single & Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects

NCT ID: NCT03894696 Not yet recruiting - Chronic Hepatitis c Clinical Trials

Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents

Start date: April 1, 2019
Phase:
Study type: Observational

The primary objective of this study is to prospectively analyse psychiatric outcomes, specifically depression and anxiety in patients with hepatitis C virus infection who are initiated on DAA therapy (sofosbuvir based regimen).

NCT ID: NCT03887637 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

Start date: March 30, 2019
Phase:
Study type: Observational

This is a multi-center, open-label clinical study. This study was aimed to assess the real-world effectiveness and safety of treatment with listed DAAs in patients with CHC and cirrhosis in Southern area of China.

NCT ID: NCT03811678 Active, not recruiting - Chronic Hepatitis c Clinical Trials

The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects

Start date: January 11, 2018
Phase: Phase 1
Study type: Interventional

The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects.

NCT ID: NCT03723824 Recruiting - Chronic Hepatitis c Clinical Trials

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Start date: February 14, 2019
Phase: Phase 4
Study type: Interventional

Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as tacrolimus, should be manageable. The aim of this study is to assess the efficacy and tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic hepatitis C after liver or kidney transplantation.

NCT ID: NCT03710252 Completed - Chronic Hepatitis C Clinical Trials

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

HEARTLAND
Start date: March 2016
Phase: Phase 4
Study type: Interventional

This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.

NCT ID: NCT03693586 Recruiting - Chronic Hepatitis c Clinical Trials

Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis

Start date: September 19, 2018
Phase:
Study type: Observational

Chronic hepatitis C infection (CHC) is usually asymptomatic; nevertheless, there are studies that show that up to two thirds of patients may present some type of extrahepatic manifestation. The most frequent extrahepatic manifestation is type II mixed cryoglobulinemia (MCG-II) and clinically the most common presentation is leukocytoclastic vasculitis (LCV) with palpable purpura that affects the lower extremities. It is estimated that up to 80% of MCG-II cases are due to CHC. Also, previous studies have demonstrated that CHC prevalence is higher in patients with autoimmune diseases compared with general population. Therefore, if vasculitis is an extrahepatic manifestation of CHC, then the prevalence of CHC infection in this group of patients could be higher than the prevalence reported in general population. The aim of the study is to know the prevalence of CHC, determined by serological rapid test for hepatitis C screening, then all positive cases will be confirmed by quantitative viral load, in patients who consult primarily to a rheumatology department for "vasculitis" or other potential hepatitis C extrahepatic manifestations (rheumatological conditions).

NCT ID: NCT03687229 Not yet recruiting - Chronic Hepatitis c Clinical Trials

The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Start date: January 2019
Phase:
Study type: Observational [Patient Registry]

The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million). It is estimated that approximately 80 % of patients with acute hepatitis C fail to eliminate the virus and become chronically infected Hepatitis C virus infection is strongly associated with the dysregulation of glucose homoeostasis such as insulin resistance and type 2 diabetes. Despite these findings of insulin resistance development via direct effects on insulin signalling pathway, the complex relationship between intrahepatic Hepatitis C virus infection and extrahepatic insulin resistance remains elusive. One of the countries most affected by Hepatitis C virus is Egypt. The Egyptian Demographic and Health Surveys measured antibody prevalence among the adult population aged 15-59 years at 10.0% in 2015—substantially higher than global levels. Several micro ribonucleic acids have been determined to play a key role in regulating viral replication and pathogenesis during infection. micro ribonucleic acid-122 expression is enriched in the liver, accounting for approximately 70 % of the total micro ribonucleic acid population in normal adult hepatocytes. Moreover, a particularly intriguing function of micro ribonucleic acid-122 involves its role in the Hepatitis C virus replication cycle. Antagonism of micro ribonucleic acid-122 not only reduces viral replication but also reduces Hepatitis C virus propagation by decreasing the expression of enzymes involved in lipid metabolism, which can enhance Hepatitis C virus replication in cell culture models.

NCT ID: NCT03673696 Recruiting - Chronic Hepatitis c Clinical Trials

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

Start date: September 4, 2018
Phase: Phase 1
Study type: Interventional

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects